BPC-157 Dosage: What Studies Used and Who Sets the Dose
Published November 19, 2026
BPC-157 dosage at a glance
| Source | Dose | Route | Who it covers |
|---|---|---|---|
| Consumer guides (Rite Aid, updated September 29, 2026) | 200 to 500 mcg, once or twice a day, four to six weeks | Subcutaneous injection | Reported clinic practice, not a trial |
| Knee pain chart review (2021) | 2 cc of a 2,000 mcg/mL solution, one injection | Into the knee joint | 12 patients in one review, 16 in the other; no control group |
| Bladder pain pilot (2024) | Not stated in the reviews | Into the bladder wall | 12 patients |
| Safety pilot (2025) | Up to 20 mg | Intravenous | 2 healthy adults |
| Animal studies | 6 mcg/kg to 20 mg/kg, up to six weeks | Injection and oral | Rats, dogs, rabbits |
Sources: a 2025 systematic review in HSS Journal and a 2025 narrative review in Current Reviews in Musculoskeletal Medicine, both linked below.
Why there is no standard dose
A standard dose comes from dose-finding trials: researchers give groups of people different amounts, then measure blood levels, benefit and side effects. BPC-157 has not been through that process. The HSS Journal review screened the literature and found 36 studies on musculoskeletal healing. 35 were in animals or cells, and one was in people.
That leaves three gaps:
- No trial has compared one dose against another in people.
- No human study has followed patients for long-term safety. The animal safety studies stopped at six weeks.
- The human studies used routes most patients never get: an injection into the knee joint, an injection into the bladder wall, and an IV infusion.
The 200 to 500 mcg figure repeated across the internet traces back to clinic practice and to scaling down animal doses. It may turn out to be reasonable. No trial has tested it.
What the studies measured
BPC-157 leaves the blood fast. The HSS Journal review reports a half-life under 30 minutes after intramuscular and intravenous doses, with the liver breaking the peptide down and the kidneys clearing it. Urine tests can detect it for four to five days.
In animals, researchers reported no toxic or lethal dose across a range from 6 mcg/kg to 20 mg/kg. They also found no organ damage on tissue exams after six weeks of dosing in rats and dogs. The same review states that it found no clinical safety data in humans.
In the 2025 pilot, two healthy adults received up to 20 mg by IV. The authors reported no adverse events and no meaningful changes in heart, liver, kidney, thyroid or metabolic lab results. Blood levels returned to baseline within 24 hours. Two people cannot show that a drug is safe.
Who sets your dose
Your prescriber does. With no approved product and no label, the dose on a BPC-157 prescription reflects the prescriber's clinical judgment about your history, your goal and the form the pharmacy makes.
Ask these before you start:
- What dose and schedule are you prescribing, and what is it based on?
- How long is the course, and what happens at the end?
- Which pharmacy compounds it, and can I see its license?
- What strength is the vial, and how many units on the syringe equal my dose?
- Which side effects mean I should stop and call you?
What changed in 2026
FDA placed BPC-157 in Category 2 in September 2023, a list of bulk drug substances that may present significant safety risks. That kept most pharmacies from compounding it. FDA removed BPC-157 from Category 2 on April 22, 2026.
On October 28, 2026, the Department of Health and Human Services published an interim enforcement discretion policy covering six peptides, BPC-157 among them. Under the policy, HHS does not intend to act against state-licensed pharmacies that compound BPC-157 acetate when ten conditions are met. The conditions include an ingredient from an FDA-registered manufacturer with a certificate of analysis, a patient-specific prescription, and a single active ingredient per product. The policy allows subcutaneous, intramuscular, oral and topical forms.
The policy does not approve BPC-157. Holland & Knight's summary notes that products compounded under it are still unapproved drugs, that HHS can revisit the policy, and that states can set stricter rules.
Safety points to know first
- Side effects lack human data. The HSS Journal review notes anonymous online reports of injection-site pain and swelling, anxiety, heart palpitations, insomnia and fatigue. No controlled human data confirms or rules these out.
- Cancer history needs a conversation. BPC-157 stimulates blood-vessel growth signals in lab studies. Tell your prescriber about any current or past cancer.
- Athletes face a ban. The World Anti-Doping Agency's 2026 Prohibited List names BPC-157 under S0, non-approved substances. It is prohibited at all times.
- "Research use only" vials are not medication. HHS wrote its 2026 policy to steer patients away from these products, which it says "pose a safety risk to US patients."
How Ozari approaches peptide therapy
Ozari Health connects patients with licensed, independent providers who review each medical history before prescribing. Licensed US pharmacies fill the prescriptions. You can see Ozari's current longevity treatments on the vitality page.
Frequently Asked Questions
What is the standard BPC-157 dose?
There is none. No human dose-finding trial exists and no BPC-157 product is FDA-approved. Consumer guides cite 200 to 500 mcg once or twice daily by subcutaneous injection, which reflects clinic practice, not trial results.
How long is a BPC-157 course?
Consumer guides commonly cite four to six weeks. Animal safety studies also ran up to six weeks, and no study has followed people longer. Your prescriber sets the length of any course.
Is BPC-157 dosed by body weight?
Animal studies dose by weight, from 6 mcg/kg to 20 mg/kg. The doses cited for people are usually flat amounts in micrograms. No human trial has compared the two approaches.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any use. Since October 28, 2026, an HHS interim policy lets state-licensed pharmacies compound it under ten conditions, and the compounded products remain unapproved drugs.
Can I take BPC-157 by mouth?
The 2026 HHS policy allows oral BPC-157 from compounding pharmacies, and it expects the pharmacy to keep documentation that the oral formulation reaches adequate bioavailability in humans. No published human trial compares oral and injected BPC-157.
Is BPC-157 banned in sports?
Yes. The World Anti-Doping Agency lists BPC-157 as a non-approved substance, prohibited in and out of competition. The NFL and UFC also name it on their banned lists.
Sources
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 2025
- Holland & Knight: HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides, November 4, 2026
- World Anti-Doping Agency: The Prohibited List, 2026
- Rite Aid: BPC-157 Peptide: Benefits, Dosage and Side Effects, updated September 29, 2026
This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. BPC-157 is not FDA-approved for any use. Individual results vary. Always consult a licensed healthcare provider before starting any prescription medication. Ozari Health is a telehealth platform that connects patients with licensed, independent healthcare providers.
Related Articles
Semaglutide and Heart Health: The Trial That Changed What These Drugs Are For
The SELECT trial found semaglutide cut heart attack, stroke, and cardiovascular death by 20% in adults without diabetes — reshaping who these drugs are for.
Read more →treatmentWhat Happens When You Stop Taking Semaglutide? The Withdrawal Trial Nobody Quotes
STEP 4 switched patients to placebo mid-treatment: most regained the weight. What the withdrawal trial means before you stop — and the restart cycle to avoid.
Read more →treatmentWhy Most People Quit GLP-1s Within a Year — and How to Beat the Odds
A 125,474-patient JAMA study found 64.8% of weight-loss GLP-1 users quit within a year — the three drivers, and what changes each one.
Read more →